

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS  
中国中文核心期刊 中国科技核心期刊 中国科学引文



CHINESE JOURNAL OF NEW DRUGS

ISSN 1003-3734  
CN 11-2850/R  
CODEN ZXZHA6

# 中國新藥雜誌



7  
2020  
Vol.29 | No.7

新型长效毒蕈碱拮抗剂revafenacin  
口腔崩解片制剂新技术及其研究进展  
严重急性呼吸综合征冠状病毒2潜在治疗药物概述  
严重急性呼吸综合征冠状病毒2突发疫情对GCP领域发展影响的调研分析  
阿哌沙班中基因毒性杂质的LC-MS/MS检查

www.newdrug.cn

ISSN 1003-3734



国家药品监督管理局主管



# 目次

半月刊 1992年创刊  
第29卷第7期 2020年4月15日出版

## •新药述评与论坛•

721 新型长效毒蕈碱拮抗剂revefenacin.....王艺花, 罗颖, 刘相奎

726 鞘氨醇-1-磷酸受体调节剂siponimod的药理作用及临床评价.....杨妍妍, 于立婷, 史爱欣

## •重大新药创制专项巡礼•

731 仿制药开发中的晶型专利规避策略.....薛亚萍, 汪东峨, 林淘曦

738 口腔崩解片制剂新技术及其研究进展.....张俊杰, 王伟, 李晨, 等

## •综述•

744 利伐沙班用于血栓栓塞性疾病的预防和治疗进展.....张学琴, 尹星烁, 王好雨, 等

## •药物临床试验规范与进展专栏•

749 抗肿瘤新药 I 期临床试验的风险管理.....赵淑华, 刘晓红, 江昊

## •抗新型冠状病毒药物研究专栏•

753 严重急性呼吸综合征冠状病毒2潜在治疗药物概述.....贾雨婷, 蔡芸, 王睿, 等

759 重大突发公共卫生事件一级响应下药物临床试验机构对驻院临床研究协调员管理要点.....董瑶, 蔡芸, 梁蓓蓓, 等

762 基于重大突发公共卫生事件 I 级响应下的药物临床试验机构中心药房管理工作指导.....贾雨婷, 蔡芸, 梁蓓蓓, 等

766 严重急性呼吸综合征冠状病毒2突发疫情对GCP领域发展影响的调研分析.....贾雨婷, 蔡芸, 梁蓓蓓, 等

773 基于分子对接技术筛选抗严重急性呼吸综合征冠状病毒2中药小分子化合物.....沈亮亮, 李勇, 周明, 等

## •实验研究•

782 网脉橐吾醇提取物抗大鼠实验性胃溃疡作用研究.....吴德松, 符德欢, 赵道强, 等

788 育阴软肝颗粒抗肝纤维化“多成分-多靶点”的网络药理学研究.....韦凌霞, 丁茂鹏, 王志旺, 等

799 吗啡-6- $\beta$ -D-葡萄糖醛酸苷的合成工艺.....郭建锋, 汪淼, 田峦嵩, 等

804 往复筒法测定非洛地平缓释片体外释放度.....袁娜娜, 程杰, 谢子立, 等

810 pH敏感聚合物胶束的制备及体外抗肿瘤活性研究.....单晚甜, 毛静, 邱立朋, 等

816 阿哌沙班中基因毒性杂质的LC-MS/MS检查.....程方洁, 付晓婷, 郝淑晓, 等

822 HPLC法测定达克替尼含量及有关物质.....阮文静, 柯尊军, 杨博, 等

## •药物安全与合理应用•

826 中药泡洗治疗卡培他滨相关重度手足综合征1例并文献回顾.....张静怡, 崔慧娟, 彭艳梅, 等

831 基于文献的中国肺栓塞患者药物治疗与国内指南符合程度的比较研究.....张静, 闫盈盈, 翟所迪

836 基于治疗药物监测的多粘菌素B用药方案优化.....陈文倩, 刘慧芳, 王芊霖, 等

[期刊基本参数] CN11-2850/R\*1992\*sm\*A4\*120\*zh\*P\*¥ 50.00\*\*21\*2020-04

责任编辑 赵文锐 英文审校 魏尔清 杜小莉 张鲸惊

# CONTENTS

CHINESE JOURNAL OF NEW DRUGS

Founded in 1992, Semimonthly  
Volume 29, Number 7  
April 15, 2020

- 721 **Revefenacin: a novel long-acting muscarinic antagonist**  
WANG Yi-hua, LUO Ying, LIU Xiang-kui
- 726 **Pharmacology and clinical evaluation of sphingosine-1-phosphate receptor modulator siponimod**  
YANG Yan-yan, YU Li-ting, SHI Ai-xin
- 731 **Crystal patent avoidance strategy for the development of generic drug**  
XUE Ya-ping, WANG Dong-e, LIN Tao-xi
- 738 **Development of new preparation technology of orally disintegrating tablets**  
ZHANG Jun-jie, WANG Wei, LI Chen, *et al*
- 744 **Progress in the prevention and treatment of thromboembolic diseases by rivaroxaban**  
ZHANG Xue-qin, YIN Xing-shuo, WANG Hao-yu, *et al*
- 749 **Risk management of phase I clinical trials of anticancer drugs**  
ZHAO Shu-hua, LIU Xiao-hong, JIANG Min
- 753 **Summary on the potential therapeutics against severe acute respiratory syndrome coronavirus 2**  
JIA Yu-ting, CAI Yun, WANG Rui, *et al*
- 759 **Key points of CRC management in hospital by drug clinical trial institutions under the first level response to major public health emergencies**  
DONG Yao, CAI Yun, LIANG Bei-bei, *et al*
- 762 **Guidance for central pharmacy management of clinical drug research institutions based on grade I response to major public health emergencies**  
JIA Yu-ting, CAI Yun, LIANG Bei-bei, *et al*
- 766 **Investigation and analysis of the impact of severe acute respiratory syndrome coronavirus 2 outbreak on the development of GCP**  
JIA Yu-ting, CAI Yun, LIANG Bei-bei, *et al*
- 773 **Screening of anti-SARS-CoV-2 small molecular compounds from traditional Chinese medicine based on molecular docking**  
SHEN Liang-liang, LI Yong, ZHOU Ming, *et al*
- 782 **Study on the effects of alcohol extract from *Ligularia dictyoneura* (Franch.) Hand.-Mazz. on experimental gastric ulcer in rats**  
WU De-song, FU De-huan, ZHAO Dao-qiang, *et al*
- 788 **"Multi-component-multi-target" Network pharmacology study of Yuyin Ruangan granules against hepatic fibrosis**  
WEI Ling-xia, DING Mao-peng, WANG Zhi-wang, *et al*
- 799 **Synthesis of morphine-6- $\beta$ -D-glucuronic acid glycosides**  
GUO Jian-feng, WANG Miao, TIAN Luan-yuan, *et al*
- 804 **Determination of *in vitro* release of felodipine sustained-release tablets by reciprocating cylinder method**  
YUAN Na-na, CHENG Jie, XIE Zi-li, *et al*
- 810 **Preparation and *in vitro* antitumor activity of pH-sensitive polymer micelles**  
SHAN Xiao-tian, MAO Jing, QIU Li-peng, *et al*
- 816 **Determination of genotoxic impurities in apixaban by LC-MS/MS**  
CHENG Fang-jie, FU Xiao-ting, GAO Shu-xiao, *et al*
- 822 **Determination of dacomitinib and related substances by HPLC**  
RUAN Wen-jing, KE Zun-jun, YANG Bo, *et al*
- 826 **Treatment of severe hand and foot syndrome caused by capecitabine with traditional Chinese medicine soaking: a case report and literature review**  
ZHANG Jing-yi, CUI Hui-juan, PENG Yan-mei, *et al*
- 831 **A comparative study on the degree of compliance between drug treatment and domestic guidelines of pulmonary embolism based on literature in China**  
ZHANG Jing, YAN Ying-ying, ZHAI Suo-di
- 836 **Dosage optimization of polymyxin B based on therapeutic drug monitoring**  
CHEN Wen-qian, LIU Hui-fang, WANG Qian-lin, *et al*

**Directed by:** National Medical Products Administration

**Sponsored by:** China Medical Science Press  
China National Pharmaceutical Group Corp.  
Chinese Pharmaceutical Association

**Editor-in-Chief:** SANG Guo-wei

**Board Chairman:** SHI Sheng-yi

**Edited by:** Editorial Board of Chinese Journal of New Drugs

**Published by:** Chinese Journal of New Drugs Co., Ltd.

**Address:** Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China

**Tel:** (010)52722697 / 52722651 / 52723707

**Website:** <http://www.newdrug.cn>

**E-mail:** [bianjibu@newdrug.cn](mailto:bianjibu@newdrug.cn)

**Printer:** Beijing Kexin Printing Co., Ltd.

**Domestic Distribution:** Beijing Post Offices

**Overseas Distribution:** China International Book Trading Corp.  
(P.O.Box 399 Beijing, China)

**Domestic Subscription:** Local Post Offices

**Periodical Registration:** ISSN 1003-3734 CN 11-2850/R

**Publication Date:** April 15, 2020

**Copyright:** 2020 by Chinese Journal of New Drugs Co., Ltd.





广告

# 改善气短乏力



## 芪参益气滴丸

- ☑ 益气通脉、活血止痛。
- ☑ 用于气虚血瘀型胸痹，症见胸闷、胸痛，气短乏力、心悸、面色少华、自汗，舌体胖有齿痕、舌质暗或紫暗或有瘀斑，脉沉或沉弦。
- ☑ 适用于冠心病、心绞痛见上述证候者

天士力医药集团股份有限公司 咨询热线 800-818-9818 400-618-9818

国药准字 Z20030139 津药广审(文)第2019120301号  
方方数据 国内定价: 50.00元

本广告仅限医学药学专业人士阅读 禁忌: 尚不明确 不良反应: 尚不明确 注意事项: 孕妇慎用。  
国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240